Rumpsfeld Markus, McDonald Stephen P, Johnson David W
Department of Renal Medicine, Level 2, Ambulatory Renal and Transplant Services Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane Qld 4102, Australia.
J Am Soc Nephrol. 2006 Jan;17(1):271-8. doi: 10.1681/ASN.2005050566. Epub 2005 Nov 23.
Although early studies observed that peritoneal membrane transport characteristics were determinants of morbidity and mortality in peritoneal dialysis (PD) patients, more recent investigations, such as the Ademex trial, have refuted these findings. The aim of this study was to determine whether baseline peritoneal transport status predicted subsequent survival in Australian and New Zealand PD patients. The study included all adult patients in Australia and New Zealand who commenced PD between April 1, 1999, and March 31, 2004, and had a peritoneal equilibration test (PET) performed within 6 mo of PD commencement. Times to death and death-censored technique failure were examined by Kaplan-Meier analyses and multivariate Cox proportional hazards models. PET measurements were available in 3702 (72%) of the 5170 individuals who began PD treatment in Australia or New Zealand during the study period. In these patients, high transporter status was found to be a significant, independent predictor of death-censored technique failure (adjusted hazard ratio [AHR] 1.23; 95% confidence interval [CI] 1.02 to 1.49; P = 0.03) and mortality (AHR 1.34; 95% CI 1.05 to 1.79, P = 0.02) compared with low-average transport status. High-average transport class was also associated with mortality (AHR 1.21; 95% CI 1.00 to 1.48; P = 0.047) but not death-censored technique failure (AHR 1.04; 95% CI 0.90 to 1.21) compared with low-average transport status. When transport status was alternatively analyzed as a continuous variable, dialysate:plasma creatinine ratio at 4 h was independently predictive of both death-censored technique failure (AHR 1.07; 95% CI 1.01 to 1.295; P = 0.031) and death (AHR 1.09; 95% CI 1.01 to 1.373; P = 0.036 per 0.1 change in dialysate:plasma creatinine). Peritoneal transport rate is a highly significant risk factor for both mortality and death-censored technique failure in the Australian and New Zealand incident PD patient populations.
尽管早期研究观察到腹膜转运特性是腹膜透析(PD)患者发病和死亡的决定因素,但最近的一些研究,如阿德梅克斯试验,反驳了这些发现。本研究的目的是确定基线腹膜转运状态是否能预测澳大利亚和新西兰PD患者的后续生存情况。该研究纳入了1999年4月1日至2004年3月31日期间在澳大利亚和新西兰开始PD治疗且在PD开始后6个月内进行了腹膜平衡试验(PET)的所有成年患者。通过Kaplan-Meier分析和多变量Cox比例风险模型检查死亡时间和死亡删失技术失败时间。在研究期间于澳大利亚或新西兰开始PD治疗的5170名个体中,有3702名(72%)可获得PET测量值。在这些患者中,与低平均转运状态相比,高转运状态被发现是死亡删失技术失败(调整后风险比[AHR]1.23;95%置信区间[CI]1.02至1.49;P = 0.03)和死亡率(AHR 1.34;95%CI 1.05至1.79,P = 0.02)的显著独立预测因素。与低平均转运状态相比,高平均转运类别也与死亡率相关(AHR 1.21;95%CI 1.00至1.48;P = 0.047),但与死亡删失技术失败无关(AHR 1.04;95%CI 0.90至1.21)。当将转运状态作为连续变量进行分析时,4小时时透析液:血浆肌酐比值可独立预测死亡删失技术失败(AHR 1.07;95%CI 1.01至1.295;P = 0.031)和死亡(AHR 1.09;95%CI 1.01至1.373;透析液:血浆肌酐每变化0.1,P = 0.036)。在澳大利亚和新西兰新发病的PD患者群体中,腹膜转运率是死亡率和死亡删失技术失败的高度显著危险因素。